Vir Biotechnology (NASDAQ:VIR – Get Free Report) and Cardiff Oncology (NASDAQ:CRDF – Get Free Report) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their institutional ownership, risk, earnings, profitability, analyst recommendations, dividends and valuation.
Profitability
This table compares Vir Biotechnology and Cardiff Oncology’s net margins, return on equity and return on assets.
| Net Margins | Return on Equity | Return on Assets | |
| Vir Biotechnology | -678.40% | -36.71% | -31.00% |
| Cardiff Oncology | -6,238.17% | -73.97% | -60.40% |
Analyst Recommendations
This is a summary of recent ratings for Vir Biotechnology and Cardiff Oncology, as provided by MarketBeat.com.
| Sell Ratings | Hold Ratings | Buy Ratings | Strong Buy Ratings | Rating Score | |
| Vir Biotechnology | 0 | 1 | 5 | 0 | 2.83 |
| Cardiff Oncology | 0 | 0 | 3 | 0 | 3.00 |
Risk and Volatility
Vir Biotechnology has a beta of 0.64, indicating that its share price is 36% less volatile than the S&P 500. Comparatively, Cardiff Oncology has a beta of 1.77, indicating that its share price is 77% more volatile than the S&P 500.
Insider and Institutional Ownership
65.3% of Vir Biotechnology shares are held by institutional investors. Comparatively, 16.3% of Cardiff Oncology shares are held by institutional investors. 15.6% of Vir Biotechnology shares are held by company insiders. Comparatively, 7.8% of Cardiff Oncology shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock is poised for long-term growth.
Valuation & Earnings
This table compares Vir Biotechnology and Cardiff Oncology”s top-line revenue, earnings per share (EPS) and valuation.
| Gross Revenue | Price/Sales Ratio | Net Income | Earnings Per Share | Price/Earnings Ratio | |
| Vir Biotechnology | $86.18 million | 15.39 | -$615.06 million | ($3.92) | -2.46 |
| Cardiff Oncology | $490,000.00 | 470.60 | -$41.44 million | ($0.94) | -4.80 |
Cardiff Oncology has lower revenue, but higher earnings than Vir Biotechnology. Cardiff Oncology is trading at a lower price-to-earnings ratio than Vir Biotechnology, indicating that it is currently the more affordable of the two stocks.
Summary
Vir Biotechnology beats Cardiff Oncology on 9 of the 14 factors compared between the two stocks.
About Vir Biotechnology
Vir Biotechnology, Inc., an immunology company, develops therapeutic products to treat and prevent serious infectious diseases. Its clinical development pipeline consists of product candidates targeting hepatitis delta virus (HDV), hepatitis B virus (HBV), and human immunodeficiency virus (HIV). The company’s preclinical candidates include those targeting influenza A and B, coronavirus disease 2019, respiratory syncytial virus (RSV) and human metapneumovirus (MPV), and human papillomavirus (HPV). The company has grant agreements with Bill & Melinda Gates Foundation and National Institutes of Health; an option and license agreement with Brii Biosciences Limited; a collaboration and license agreement with Alnylam Pharmaceuticals, Inc.; license agreements with MedImmune, LLC; collaboration with WuXi Biologics (Hong Kong) Limited and Glaxo Wellcome UK Ltd.; and a collaborative research agreement with GlaxoSmithKline Biologicals S.A, as well as license agreement with Sanofi for three clinical-stage masked T-cell engagers (TCEs) and exclusive use of the protease-cleavable masking platform for oncology and infectious diseases. It also has a manufacturing agreement with Samsung Biologics Co.,Ltd. The company was incorporated in 2016 and is headquartered in San Francisco, California.
About Cardiff Oncology
Cardiff Oncology, Inc., a clinical-stage biotechnology company, develops novel therapies to treat various cancers in California. Its lead drug candidate is onvansertib, an oral selective Polo-like Kinase 1 Inhibitor to treatment a range of solid tumor cancers and KRAS/NRAS-mutated metastatic colorectal and metastatic pancreatic cancer, as well as investigator-initiated trials in triple negative breast cancer and small cell lung cancer; and TROV-054 is a Phase 1b/2 for FOLFIRI and bevacizumab. The company primarily serves pharmaceutical manufacturers. The company was formerly known as Trovagene, Inc. and changed its name to Cardiff Oncology, Inc. in May 2012. Cardiff Oncology, Inc. was incorporated in 1999 and is headquartered in San Diego, California.
Receive News & Ratings for Vir Biotechnology Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Vir Biotechnology and related companies with MarketBeat.com's FREE daily email newsletter.
